Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Recaticimab by Jiangsu Hengrui Medicine for Heterozygous familial hypercholesterolemia (heFH): Likelihood of Approval
Recaticimab is under clinical development by Jiangsu Hengrui Medicine and currently in Phase III for Heterozygous familial hypercholesterolemia (heFH). According...